US 12,343,341 B2
Synthetic lethality and the treatment of cancer
Luc G. Berthiaume, Edmonton (CA); Erwan Beauchamp, Rennes (FR); Conganige Maneka Anne Perinpanayagam, Edmonton (CA); and Chuiyee Yap, Edmonton (CA)
Assigned to PACYLEX PHARMACEUTICALS INC., Calgary (CA)
Filed by PACYLEX PHARMACEUTICALS INC., Calgary (CA)
Filed on Oct. 1, 2021, as Appl. No. 17/492,427.
Application 17/492,427 is a continuation of application No. 16/025,835, filed on Jul. 2, 2018, granted, now 11,135,218.
Application 16/025,835 is a continuation of application No. 14/234,312, abandoned, previously published as PCT/CA2012/000696, filed on Jul. 23, 2012.
Claims priority of provisional application 61/510,686, filed on Jul. 22, 2011.
Prior Publication US 2022/0023294 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 31/12 (2006.01); A61K 31/191 (2006.01); A61K 31/28 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); C07K 16/40 (2006.01); C12Q 1/686 (2018.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 31/12 (2013.01); A61K 31/191 (2013.01); A61K 31/28 (2013.01); A61K 31/7105 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C07K 16/40 (2013.01); C12Q 1/686 (2013.01); G01N 33/5091 (2013.01); G01N 33/574 (2013.01); G01N 33/57496 (2013.01)] 11 Claims
 
1. A method of treating a cancer in a human subject, comprising:
identifying that the human subject is suitable for treatment with an inhibitor of NMT1 protein by
measuring an N-myristoyltransferase 1 (NMT1) protein level in a sample containing cancer cells obtained from the human subject using a device configured to measure NMT1 protein,
measuring an N-myristoyltransferase 2 (NMT2) protein level in the sample containing cancer cells using a device configured to measure NMT2 protein,
determining from the measured NMT1 and NMT2 protein levels that NMT1 protein is present in the sample containing cancer cells and that the NMT2 protein level in the sample containing cancer cells is low or absent as compared to an NMT2 protein level present in a normal human B-Cell, thereby identifying the human subject as suitable for treatment with the inhibitor of NMT1 protein; and
administering the inhibitor of NMT1 inhibitor to the human subject, wherein said NMT1 inhibitor is DDD85646, or a derivative thereof.